Rheumatoid Arthritis
Age, racial gaps in b/tsDMARD use for rheumatoid arthritis show ‘surprising’ stability
WASHINGTON — Disparities in the use of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis, including among older, Black and Asian patients, have not changed in 10 years, according to data.
Exposure to DDT, other pesticides exhibits ‘strong’ risk for rheumatoid arthritis
WASHINGTON — Exposure to specific pesticides, including DDT, demonstrates “strong and significant” risks for rheumatoid arthritis among the female spouses of pesticide applicators, according to a study presented at ACR Convergence 2024.
IL-6, JAK inhibitors, rituximab increase severe infection risk in inflammatory arthritis
WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.
Older, Asian patients less likely to receive b/ts DMARDs for rheumatoid arthritis
Patients with rheumatoid arthritis aged younger than 40 years are more than twice as likely to receive biologic or targeted synthetic disease-modifying anti-rheumatic drugs vs. older individuals, according to data.
Traumatic stress creates ‘feedback loop that perpetuates’ autoimmune rheumatic diseases
Despite a lack of research in the area, there is significant evidence that traumatic stress contributes to the onset and worsening of autoimmune rheumatic diseases, according to a review published in Seminars in Arthritis and Rheumatism.
Certolizumab pegol superior to adalimumab in patients with rheumatoid arthritis, high RF
Patients with rheumatoid arthritis and high rheumatoid factor demonstrate better clinical outcomes, and maintain drug concentration, when treated with certolizumab pegol vs. adalimumab, according to data published in Rheumatology.
Patients with rheumatoid arthritis starting bDMARDs have higher ILD risk vs those with PsA
Patients with rheumatoid arthritis or psoriatic arthritis starting biologic disease-modifying antirheumatic drugs have a higher risk for interstitial lung disease vs. the general population, with the highest risk found in RA, data show.
Hypertension common, predicted by older age, diabetes in early rheumatoid arthritis
Hypertension is common in patients with early rheumatoid arthritis, and most frequently develops in older patients and those with traditional cardiovascular risk factors, according to data published in Rheumatology Advances in Practice.
Early data offer ‘hopeful’ results for vagus nerve stimulation in rheumatoid arthritis
SAN DIEGO — Vagus nerve stimulation may represent a “novel therapeutic option” for patients with rheumatoid arthritis, according to data presented at the 2024 Congress of Clinical Rheumatology West.
Obesity dampens rheumatoid arthritis treatment effectiveness, satisfaction
SAN DIEGO — Obesity represents a significant barrier to treatment effectiveness, and by extension treatment satisfaction, in rheumatoid arthritis, according to data presented at the 2024 Congress of Clinical Rheumatology West.